Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice.

Perera Y, Farina HG, Hernández I, Mendoza O, Serrano JM, Reyes O, Gómez DE, Gómez RE, Acevedo BE, Alonso DF, Perea SE.

Int J Cancer. 2008 Jan 1;122(1):57-62.

2.

Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2).

Perea SE, Reyes O, Puchades Y, Mendoza O, Vispo NS, Torrens I, Santos A, Silva R, Acevedo B, López E, Falcón V, Alonso DF.

Cancer Res. 2004 Oct 1;64(19):7127-9.

3.

CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.

Perea SE, Reyes O, Baladron I, Perera Y, Farina H, Gil J, Rodriguez A, Bacardi D, Marcelo JL, Cosme K, Cruz M, Valenzuela C, López-Saura PA, Puchades Y, Serrano JM, Mendoza O, Castellanos L, Sanchez A, Betancourt L, Besada V, Silva R, López E, Falcón V, Hernández I, Solares M, Santana A, Díaz A, Ramos T, López C, Ariosa J, González LJ, Garay H, Gómez D, Gómez R, Alonso DF, Sigman H, Herrera L, Acevedo B.

Mol Cell Biochem. 2008 Sep;316(1-2):163-7. doi: 10.1007/s11010-008-9814-5. Epub 2008 Jun 25.

PMID:
18575815
4.

Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity.

Perera Y, Farina HG, Gil J, Rodriguez A, Benavent F, Castellanos L, Gómez RE, Acevedo BE, Alonso DF, Perea SE.

Mol Cancer Ther. 2009 May;8(5):1189-96. doi: 10.1158/1535-7163.MCT-08-1056. Epub 2009 May 5.

5.

CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor.

Scaglioni PP, Yung TM, Choi S, Baldini C, Konstantinidou G, Pandolfi PP.

Mol Cell Biochem. 2008 Sep;316(1-2):149-54. doi: 10.1007/s11010-008-9812-7. Epub 2008 Jun 20. Erratum in: Mol Cell Biochem. 2009 Jul;327(1-2):279. Choi, S C [corrected to Choi, S].

PMID:
18566754
6.

Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse models.

Vallespí MG, Pimentel G, Cabrales-Rico A, Garza J, Oliva B, Mendoza O, Gomez Y, Basaco T, Sánchez I, Calderón C, Rodriguez JC, Markelova MR, Fichtner I, Astrada S, Bollati-Fogolín M, Garay HE, Reyes O.

J Pept Sci. 2014 Nov;20(11):850-9. doi: 10.1002/psc.2676. Epub 2014 Jul 20.

PMID:
25044757
7.

CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo.

Farina HG, Benavent Acero F, Perera Y, Rodríguez A, Perea SE, Castro BA, Gomez R, Alonso DF, Gomez DE.

Exp Cell Res. 2011 Jul 15;317(12):1677-88. doi: 10.1016/j.yexcr.2011.04.011. Epub 2011 May 1.

PMID:
21565189
8.
9.

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.

Diaz R, Nguewa PA, Parrondo R, Perez-Stable C, Manrique I, Redrado M, Catena R, Collantes M, Peñuelas I, Díaz-González JA, Calvo A.

BMC Cancer. 2010 May 11;10:188. doi: 10.1186/1471-2407-10-188.

10.

CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.

Perea SE, Baladron I, Garcia Y, Perera Y, Lopez A, Soriano JL, Batista N, Palau A, Hernández I, Farina H, Garcia I, Gonzalez L, Gil J, Rodriguez A, Solares M, Santana A, Cruz M, Lopez M, Valenzuela C, Reyes O, López-Saura PA, González CA, Diaz A, Castellanos L, Sanchez A, Betancourt L, Besada V, González LJ, Garay H, Gómez R, Gómez DE, Alonso DF, Perrin P, Renualt JY, Sigman H, Herrera L, Acevedo B.

Mol Cell Biochem. 2011 Oct;356(1-2):45-50. doi: 10.1007/s11010-011-0950-y. Epub 2011 Jul 7.

PMID:
21735096
11.

Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library.

Hung MS, Xu Z, Lin YC, Mao JH, Yang CT, Chang PJ, Jablons DM, You L.

BMC Cancer. 2009 May 6;9:135. doi: 10.1186/1471-2407-9-135.

12.

Phosphorylation of apoptosis repressor with caspase recruitment domain by protein kinase CK2 contributes to chemotherapy resistance by inhibiting doxorubicin induced apoptosis.

Wang J, Feng C, He Y, Ding W, Sheng J, Arshad M, Zhang X, Li P.

Oncotarget. 2015 Sep 29;6(29):27700-13. doi: 10.18632/oncotarget.4392.

13.

Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.

Solares AM, Santana A, Baladrón I, Valenzuela C, González CA, Díaz A, Castillo D, Ramos T, Gómez R, Alonso DF, Herrera L, Sigman H, Perea SE, Acevedo BE, López-Saura P.

BMC Cancer. 2009 May 13;9:146. doi: 10.1186/1471-2407-9-146.

14.

Chimeric peptides as modulators of CK2-dependent signaling: Mechanism of action and off-target effects.

Zanin S, Sandre M, Cozza G, Ottaviani D, Marin O, Pinna LA, Ruzzene M.

Biochim Biophys Acta. 2015 Oct;1854(10 Pt B):1694-707. doi: 10.1016/j.bbapap.2015.04.026. Epub 2015 Apr 30.

PMID:
25936516
15.

Antitumoral activity of allosteric inhibitors of protein kinase CK2.

Moucadel V, Prudent R, Sautel CF, Teillet F, Barette C, Lafanechere L, Receveur-Brechot V, Cochet C.

Oncotarget. 2011 Dec;2(12):997-1010.

16.

Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.

Qu Y, Wu X, Yin Y, Yang Y, Ma D, Li H.

J Exp Clin Cancer Res. 2014 Jun 17;33:52. doi: 10.1186/1756-9966-33-52.

17.

Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt.

Hohla F, Schally AV, Kanashiro CA, Buchholz S, Baker B, Kannadka C, Moder A, Aigner E, Datz C, Halmos G.

Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18671-6. Epub 2007 Nov 14.

18.

Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft model.

Hung MS, Xu Z, Chen Y, Smith E, Mao JH, Hsieh D, Lin YC, Yang CT, Jablons DM, You L.

Int J Oncol. 2013 Nov;43(5):1517-22. doi: 10.3892/ijo.2013.2087. Epub 2013 Sep 4.

19.

JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.

Manthey CL, Johnson DL, Illig CR, Tuman RW, Zhou Z, Baker JF, Chaikin MA, Donatelli RR, Franks CF, Zeng L, Crysler C, Chen Y, Yurkow EJ, Boczon L, Meegalla SK, Wilson KJ, Wall MJ, Chen J, Ballentine SK, Ott H, Baumann C, Lawrence D, Tomczuk BE, Molloy CJ.

Mol Cancer Ther. 2009 Nov;8(11):3151-61. doi: 10.1158/1535-7163.MCT-09-0255. Epub 2009 Nov 3.

20.

Supplemental Content

Support Center